38 filings · most recent first
SLNO 8-K Filings
Soleno Therapeutics Withdraws Maa For Viokat In Europe
Neurocrine Biosciences To Acquire Soleno Therapeutics In 29 Billion Deal
Soleno Therapeutics Amends And Restates Bylaws
Soleno Therapeutics Appoints Jennifer Fulk As New Cfo
Soleno Therapeutics Reports Successful Launch Of Vykat Xr And 2025 Financial
Soleno Therapeutics Announces Executive Compensation And Severance Plan Updates
Soleno Therapeutics Announces Preliminary Q4 And Fullyear 2025 Financial Results
Soleno Therapeutics Announces 100M Share Repurchase
Soleno Therapeutics Reports Third Quarter 2025 Financial Results And Us Launch
Soleno Therapeutics Appoints Experienced Cfo Mark W Hahn To Board
Soleno Therapeutics Reports Serious Adverse Event To Fda
Soleno Therapeutics Announces Investor Roadshow And Launch Of Vykat Xr
Soleno Therapeutics Reports Second Quarter 2025 Financial Results And Updates
Soleno Therapeutics Announces 200 Million Public Offering Of Common Stock
Soleno Therapeutics Announces Preliminary Financial Results For Q2 2025
Soleno Therapeutics Announces 2025 Annual Meeting Voting Results
Soleno Therapeutics Announces Fda Approval And Q1 2025 Financial Results
Soleno Therapeutics Engages New Auditor Following Resignation Of Marcum Llp
Soleno Therapeutics Receives Fda Approval For Vykat Xr To Treat Hyperphagia In
Soleno Therapeutics Reports Fullyear 2024 Financial Results And Provides
Soleno Therapeutics Announces Executive Compensation Changes
Soleno Therapeutics Announces 200 Million Debt Financing With Oxford Finance Llc
Fda Extends Review Period For Soleno Therapeutics Dccr Nda By Three Months
Soleno Therapeutics Announces Fda Acceptance Of Nda For Dccr And Third Quarter
Soleno Therapeutics Announces Board Updates
Soleno Therapeutics Reports Q2 2024 Financial Results And Corporate Update
Soleno Therapeutics Announces Agreement For Common Stock Sale
Soleno Therapeutics Announces Performancebased Stock Awards For Executives
Soleno Therapeutics Submits Nda For Dccr To Treat Praderwilli Syndrome
Soleno Therapeutics Enters New Office Lease
Soleno Therapeutics Annual Meeting Voting Results Announced
Soleno Therapeutics Reports First Quarter 2024 Financial Results And Corporate
Soleno Therapeutics Announces Pricing For Public Offering Of Common Stock
Soleno Therapeutics Receives Breakthrough Therapy Designation For Dccr In Pws
Soleno Therapeutics Director Gwen Melincoff To Not Stand For Reelection
Soleno Therapeutics Reports Fourth Quarter And Fullyear 2023 Financial Results
Soleno Therapeutics Amends Inducement Equity Plan
Soleno Therapeutics Announces Executive Compensation Adjustments For 2024